<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171379</url>
  </required_header>
  <id_info>
    <org_study_id>CERL080AIT01</org_study_id>
    <nct_id>NCT00171379</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant</brief_title>
  <official_title>Open-label Study to Evaluate the Tolerability, Safety and Efficacy of the Equimolar Conversion From Mycophenolate Mofetil (MMF) to Enteric-Coated Mycophenolate Sodium (EC-MPS) in Patients With Renal Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the safety and efficacy of equimolar conversion from MMF
      to enteric-coated mycophenolate sodium, in renal transplant patients receiving cyclosporine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function, measured as calculated creatinine clearance according to the Cockcroft and Gault formula</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy proven acute rejection</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Gastrointestinal disturbances as measured by visual analog scales (upper and lower gastrointestinal symptoms)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life related to GI symptoms (GIQLI scale)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full blood count</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Adverse Events (check-list)</measure>
  </secondary_outcome>
  <enrollment type="Actual">162</enrollment>
  <condition>Prevention of Acute Rejection After Kidney Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric-Coated Mycophenolate Sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First or second (single or double) deceased or living donor kidney transplant received
             at least six months previously;

               -  Immunosuppressive therapy with cyclosporin and mycophenolate mofetil (MMF);

               -  Receiving an MMF dose of &lt;2/g/day because of any adverse event and/or altered
                  laboratory test result attributed to MMF

        Exclusion Criteria:

          -  â€¢ Subjects expected to discontinue cyclosporin therapy;

               -  Patients with thrombocytopenia (&lt;75,000/mm3), an absolute neutrophil count of
                  &lt;1,500/mm3 and/or leukopenia (&lt;2,500/mm3), or anemia (hemoglobin &lt;6 g/dl) at
                  baseline;

               -  Patients experiencing an acute rejection in the previous two months, with
                  inadequate (creatininemia &gt;2.5 mg/dL) or worsening renal function in the previous
                  two months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>February 1, 2011</last_update_submitted>
  <last_update_submitted_qc>February 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Novartis External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Kidney transplantation; acute rejection; gastrointestinal adverse events; quality of life; mycophenolate sodium.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

